Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.
et al., 2023, GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification., Nat Genet, Vol:55, Pages:1448-1461
et al., 2023, The effects of kisspeptin on food intake in women with overweight or obesity, Diabetes, Obesity and Metabolism: a Journal of Pharmacology and Therapeutics, Vol:25, ISSN:1462-8902, Pages:2393-2397
et al., 2023, 100 years of glucagon and 100 more., Diabetologia, Vol:66, Pages:1378-1394
et al., 2023, The Accuracy of Continuous Glucose Sensors in People with Diabetes Undergoing Hemodialysis (ALPHA Study)., Diabetes Technol Ther, Vol:25, Pages:447-456
et al., 2023, Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: a secondary analysis of a randomized single-blind placebo-controlled study, Diabetes, Obesity and Metabolism: a Journal of Pharmacology and Therapeutics, Vol:25, ISSN:1462-8902, Pages:1731-1739